Vaccination

Genetec Q2FY2022 PAT Up by Sixfold

Monday, October 25, 2021 - 10:00am

Genetec also announced their proposal of a bonus issue of 661,564,800 new ordinary shares in Genetec ("Bonus Shares") on the basis of twelve (12) Bonus Shares for every one (1) existing ordinary share in Genetec ("Genetec Share" or "Share") held on an entitlement date to be determined later ("Proposed Bonus Issue").

Key Points: 
  • Genetec also announced their proposal of a bonus issue of 661,564,800 new ordinary shares in Genetec ("Bonus Shares") on the basis of twelve (12) Bonus Shares for every one (1) existing ordinary share in Genetec ("Genetec Share" or "Share") held on an entitlement date to be determined later ("Proposed Bonus Issue").
  • The Entitlement Date will be determined and announced at a later date upon receipt of all relevant approvals for the Proposed Bonus Issue.
  • Earnings per share stood at 31.25 sen (fully diluted) in Q2FY2022 compared to EPS of 6.18 sen in Q2FY2021.
  • For the first-half of the financial year ended 31 March 2022 ("1HFY2022"), the Company recorded 2884% higher PAT of RM24.50 million compared to the corresponding period of the previous financial year, when the Company posted PAT of RM821,000.

SnapNurse Joins DLH in Alaska's Fight Against COVID-19

Monday, October 25, 2021 - 12:00pm

SnapNurse will rapidly deploy hundreds of highly-trained medical personnel to the state of Alaska in support of two FEMA contracts recently awarded to DLH.

Key Points: 
  • SnapNurse will rapidly deploy hundreds of highly-trained medical personnel to the state of Alaska in support of two FEMA contracts recently awarded to DLH.
  • Through the first contract, DLH and its partners will provide medical countermeasures and emergency medical services for hospitals, long-term care facilities, and schools throughout the state.
  • SnapNurse will place experienced medical support personnel in communities throughout the state, with DLH will providing emergency medical logistics coordination for the healthcare services team.
  • We are proud to partner with DLH to staff this important contract with FEMA, said Cherie Kloss, SnapNurse founder and CEO.

Lion Electric Receives Conditional Purchase Order from Student Transportation of Canada for 1,000 Electric School Buses

Monday, October 25, 2021 - 11:30am

If confirmed, this purchase order would allow STC to become the largest operator of zero-emission school buses in North America.

Key Points: 
  • If confirmed, this purchase order would allow STC to become the largest operator of zero-emission school buses in North America.
  • The operator plans on working closely with its customers and partners to determine which school boards would adopt the electric buses if fulfilled.
  • "We applaud STC for its leadership and vision to accelerate the deployment of all-electric school buses in Canada, and we thank them for trusting Lion with such an important transition" said MarcBedard, CEO Founder of Lion Electric.
  • Founded in 1997, Student Transportation of America (STA) is an industry leader in school transportation, safety and fleet services.

COVID-19: Does having received the BCG vaccine as a child provide a protective effect?

Monday, October 25, 2021 - 11:00am

The research , published in the Vaccine journal, brings new light on the possible link between the BCG vaccine and COVID-19.

Key Points: 
  • The research , published in the Vaccine journal, brings new light on the possible link between the BCG vaccine and COVID-19.
  • "Our study has shownconvincingly that BCG, a strong stimulator of innate immunity, does not confer very long-term protection against COVID-19.
  • Among those who tested positive for COVID-19, 54% had received the BCG vaccine during childhood.
  • Among those who had received the vaccine more recently, in the early 1970s, no protective effect was also observed.

PJSC Magnitogorsk Iron and Steel Works: MMK Group IFRS financial results for Q3 and 9M 2021

Monday, October 25, 2021 - 9:02am

MMK Group's revenue decreased by 6.9% quarter-on-quarter (q-o-q) to USD 3,031 mln, which reflects a decline in sales volumes partially offset by higher global steel prices.

Key Points: 
  • MMK Group's revenue decreased by 6.9% quarter-on-quarter (q-o-q) to USD 3,031 mln, which reflects a decline in sales volumes partially offset by higher global steel prices.
  • EBITDA declined by 19.4% q-o-q to USD 1,157 mln, mainly due to lower revenue and the impact of export duties.
  • Close to 80% of Group employees were vaccinated by the end of Q3 2021.
  • The ESG Reporting Awards 2021 by ESG Investing recognised MMK Group's non-financial reporting among the world's best in the Metals & Mining category.

Josip Heit comments on the current situation of dealing with the coronavirus

Monday, October 25, 2021 - 8:00am

Germany has been waiting for this prospect since March 2020, when the "epidemic situation of national importance" was first declared by the Bundestag.

Key Points: 
  • Germany has been waiting for this prospect since March 2020, when the "epidemic situation of national importance" was first declared by the Bundestag.
  • The German economy suffered massively from the coronavirus, as did all economies on our planet.
  • Most recently, the 7-day incidence in Germany - of people infected with the coronavirus - rose again to 72.7 percent.
  • Heit says: "One can only hope that humanity has learned from this tragedy!

Lancet's EClinicalMedicine publishes phase 2 data on C21 in COVID-19

Monday, October 25, 2021 - 7:47am

STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ) ("Vicore"), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the results of the COVID-19 phase 2 trial of its angiotensin II type 2 receptor agonist C21 have been published in EClinicalMedicine, a peer reviewed clinical journal, published by The Lancet. The paper is available online via this link.

Key Points: 
  • - Data encouraged Vicore to move into phase 3 with readout on-track for H1 2022.
  • In this 106 patient phase 2 trial, data suggest that treatment with C21 may have reduced progression to more severe respiratory disease.
  • The pivotal phase 3 trial ATTRACT-32was approved by the FDA in June 2021 based on results from the ATTRACT trial.
  • The compound is currently in a phase 2 proof-of-concept trial in IPF and in a pivotal phase 3 trial in COVID-19.

Lancet's EClinicalMedicine publishes phase 2 data on C21 in COVID-19

Monday, October 25, 2021 - 7:39am

The phase 2 trial ATTRACT1was organized and conducted in the full heat of the 2020 COVID-19 outbreak.

Key Points: 
  • The phase 2 trial ATTRACT1was organized and conducted in the full heat of the 2020 COVID-19 outbreak.
  • In this 106 patient phase 2 trial, data suggest that treatment with C21 may have reduced progression to more severe respiratory disease.
  • The pivotal phase 3 trial ATTRACT-32was approved by the FDA in June 2021 based on results from the ATTRACT trial.
  • The compound is currently in a phase 2 proof-of-concept trial in IPF and in a pivotal phase 3 trial in COVID-19.

Hawaiian Airlines Resumes Nonstop Sydney-Honolulu Service

Monday, October 25, 2021 - 1:15am

Hawaiian Airlines last month also launched a new in-flight video encouraging visitors to Travel Pono (responsibly) by enjoying Hawai'i safely and responsibly.

Key Points: 
  • Hawaiian Airlines last month also launched a new in-flight video encouraging visitors to Travel Pono (responsibly) by enjoying Hawai'i safely and responsibly.
  • Consumer surveys by Cond Nast Traveler, Travel + Leisure and TripAdvisor have placed Hawaiian among the top of all domestic airlines serving Hawaii.
  • Hawaiian offers approximately 130 flights within the Hawaiian Islands, daily nonstop flights between Hawaii and 16 U.S. gateway cities more than any other airline as well as once-weekly service connecting Honolulu and Tahiti and flights between Honolulu and American Samoa.
  • Hawaiian Airlines, Inc. is a subsidiary of Hawaiian Holdings, Inc. (NASDAQ: HA).

Novavax, Inc. Investors: Company Investigated by the Portnoy Law Firm

Friday, October 22, 2021 - 8:40pm

​LOS ANGELES, Oct. 22, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Key Points: 
  • LOS ANGELES, Oct. 22, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novavax, Inc. (Novavax or the Company) (NASDAQ: NVAX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • On October 19, 2021, Politico published an article entitled They rushed the process: Vaccine makers woes hamper global inoculation campaign.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.